Myovant Sciences Ltd (MYOV) is a clinical-stage biopharmaceutical company. It’s focus is on developing therapies for the treatment women’s health and endocrine diseases and its best candidate is a product called Relugolix, which inhibits GnRH from affecting the anterior pituitary. The company is also eyeing the use of Relugolix for the use of treating advanced […]